Poster Presentations 2024
All the posters shown in the Poster Hall at AMMF’s Hybrid European Cholangiocarcinoma Conference 2024 can be seen here.
Please note: This area is intended for HCPs only.
1. Jean Fan, TransThera Sciences (US)
FIRST-308: Phase III Study of tinengotinib versus physician’s choice in subjects with FGFR-altered, chemotherapy- and FGFR inhibitor-refractory/relapsed cholangiocarcinoma (CCA)
To view the poster, click here.
2. Kemi Kostrzynski, AstraZeneca UK
Consideration of a biliary tract cancer (BTC) diagnosis in liver-involved cancer of unknown primary (CUP)
To view the poster, click here.
3. Aporn Wangwiwatsin, Khon Kaen University, Thailand
Extrachromosomal circular DNA in cholangiocarcinoma: exploring potential functions in RAS/BRAF signalling
To view the poster, click here.
4. Caitlin McCaffrey, University of Edinburgh
Hepatocyte plasticity: insights from the periportal and pericentral zones
To view the poster, click here.
5. Lara Heij, University Hospital Essen
Nerve fibers in the tumor microenvironment as a novel biomarker for oncological outcome in patients undergoing surgery for perihilar cholangiocarcinoma
To view the poster, click here.
6. Lara Heij, University Hospital Essen
Transcriptomic analysis reveals macrophage and NK cell interaction to be upregulated in cholangiocarcinoma patients with a poor outcome
To view the poster, click here.
7. John Bridgewater, UCL Cancer Institute, London
Zanidatamab in previously treated HER2+ biliary tract cancer (BTC): impact on patient-reported pain outcomes in the Phase 2b HERIZON-BTC-01 study
To view the poster, click here.
8. Harry Daniels, University Hospitals Birmingham NHS Foundation Trust
UK real world evidence of using durvalumab plus gemcitabine and cisplatin for biliary tract cancers in an early access scheme
To view the poster, click here.
9. Juan W Valle, Cholangiocarcinoma Foundation, USA
Three-year survival and safety update from the Phase 3 TOPAZ-1 study of durvalumab plus chemotherapy in biliary tract cancer
To view the poster, click here.
10. Ricardo Roque, Portuguese Institute of Oncology of Coimbra
Ivosidenib as a rescue treatment in a symptomatic patient with advanced cholangiocarcinoma
To view the poster, click here.
11. Ricardo Roque, Portuguese Institute of Oncology of Coimbra
Pemigatinib benefit in a high burden cholangiocarcinoma with a rare FGFR2 single-nucleotide variant
To view the poster, click here.
12. Zhen Wang, West China Hospital, Sichuan University, China
CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma
To view the poster, click here.
13. Haichuan Wang, West China Hospital, Sichuan University, China
CLK1 overexpression synergized with AKT activation to promote intrahepatic cholangiocarcinogenesis
To view the poster, click here.
14. Yong Zeng, West China Hospital, Sichuan University, China
CircNFIB inhibits tumor growth and metastasis through suppressing MEK1/ERK signalling in intrahepatic cholangiocarcinoma
To view the poster, click here.
15. Kefei Yuan, West China Hospital, Sichuan University, China
IL-6-induced cGGNBP2 encodes a protein to promote cell growth and metastasis in intrahepatic cholangiocarcinoma
To view the poster, click here.
16. Jin Zhou, West China Hospital, Sichuan University, China
Target P13K sensitizes FGFR inhibitor in cholangiocarcinoma
To view the poster, click here.
17. Colin Rae, University of Glasgow
Establishment of 3-dimensional organoids from biliary cancer
18. Thomas Crellen, University of Glasgow and Wellcome Sanger Institute, UK
Evolution and latency of liver fluke-induced cholangiocarcinoma
To view the poster, click here.
19. Talha Mukhtar, Royal Free London NHS Foundation Trust
Assessing adherence and cost implications of NICE Guidelines for intravenous compared to oral paracetamol use after resuming oral diet following liver and pancreas resections
To view the poster, click here.
